Related references
Note: Only part of the references are listed.Diffuse Intratumoral Stromal Inflammation in Ovarian Clear Cell Carcinoma is Associated With Loss of Mismatch Repair Protein and High PD-L1 Expression
Shih-Yao Lin et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2021)
Evaluation of SWI/SNF Protein Expression by Immunohistochemistry in Ovarian Clear Cell Carcinoma
Jennifer A. Bennett et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2021)
SWI/SNF-deficient malignancies of the female genital tract
W. Glenn McCluggage et al.
SEMINARS IN DIAGNOSTIC PATHOLOGY (2021)
An expanded universe of cancer targets
William C. Hahn et al.
CELL (2021)
Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
Shogo Shigeta et al.
MOLECULAR CANCER THERAPEUTICS (2021)
An acetyl-histone vulnerability in PI3K/AKT inhibition-resistant cancers is targetable by both BET and HDAC inhibitors
Di Wu et al.
CELL REPORTS (2021)
Efficacy of glutathione inhibitors for the treatment of ARID1A-deficient diffuse-type gastric cancers
Mariko Sasaki et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)
Incidence of endometrioid and clear-cell ovarian cancer in histological proven endometriosis: the ENOCA population-based cohort study
Marjolein Hermens et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2020)
Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents
Loredana Cappellacci et al.
CURRENT MEDICINAL CHEMISTRY (2020)
Rethinking of treatment strategies and clinical management in ovarian clear cell carcinoma
Kazuaki Takahashi et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)
Pan-cancer analysis of whole genomes
Peter J. Campbell et al.
NATURE (2020)
The SWI/SNF complex in cancer - biology, biomarkers and therapy
Priya Mittal et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
SWI/SNF inactivation in the endometrial epithelium leads to loss of epithelial integrity
Jake J. Reske et al.
HUMAN MOLECULAR GENETICS (2020)
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
Franck Morschhauser et al.
LANCET ONCOLOGY (2020)
ARID1A Mutations Promote P300-Dependent Endometrial Invasion through Super-Enhancer Hyperacetylation
Mike R. Wilson et al.
CELL REPORTS (2020)
Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers
Hideaki Ogiwara et al.
CANCER CELL (2019)
Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: A JSGO-JSOG joint study
Hiroko Machida et al.
GYNECOLOGIC ONCOLOGY (2019)
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer Phase 1b Results From the JAVELIN Solid Tumor Trial
Mary L. Disis et al.
JAMA ONCOLOGY (2019)
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
U. A. Matulonis et al.
ANNALS OF ONCOLOGY (2019)
Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype
Masataka Takenaka et al.
CLINICAL CANCER RESEARCH (2019)
Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma
Joseph J. Caumanns et al.
CANCER LETTERS (2019)
ARID1A and PI3-kinase pathway mutations in the endometrium drive epithelial transdifferentiation and collective invasion
Mike R. Wilson et al.
NATURE COMMUNICATIONS (2019)
Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis
Amilcar Barreta et al.
HUMAN PATHOLOGY (2019)
Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma
Takafumi Kuroda et al.
GYNECOLOGIC ONCOLOGY (2019)
Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes
Tuan Zea Tan et al.
EBIOMEDICINE (2019)
Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing
Yusuke Shibuya et al.
GENES CHROMOSOMES & CANCER (2018)
ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade
Jianfeng Shen et al.
NATURE MEDICINE (2018)
ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors
Katrien Berns et al.
ONCOGENE (2018)
Histone deacetylase 6 in cancer
Ting Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Clonal Expansion and Diversification of Cancer-Associated Mutations in Endometriosis and Normal Endometrium
Kazuaki Suda et al.
CELL REPORTS (2018)
Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor
Miriam Franklin et al.
CANCER MEDICINE (2018)
Modular Organization and Assembly of SWI/SNF Family Chromatin Remodeling Complexes
Nazar Mashtalir et al.
CELL (2018)
Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines
Eniko Papp et al.
CELL REPORTS (2018)
A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium
Stephanie Lheureux et al.
CLINICAL CANCER RESEARCH (2018)
Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference
Ji Yon Agnes Jang et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2017)
Clinical statistics of gynecologic cancers in Japan
Wataru Yamagami et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2017)
Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium
Brian C. Willis et al.
MODERN PATHOLOGY (2017)
ARID1A-mutated ovarian cancers depend on HDAC6 activity
Benjamin G. Bitler et al.
NATURE CELL BIOLOGY (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
Cancer-Associated Mutations in Endometriosis without Cancer
M. S. Anglesio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
AACR Project GENIE: Powering Precision Medicine through an International Consortium
Fabrice Andre et al.
CANCER DISCOVERY (2017)
Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression
Brooke E. Howitt et al.
ONCOIMMUNOLOGY (2017)
Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference
M. A. Bookman et al.
ANNALS OF ONCOLOGY (2017)
Exome Sequencing Landscape Analysis in Ovarian Clear Cell Carcinoma Shed Light on Key Chromosomal Regions and Mutation Gene Networks
Ryusuke Murakami et al.
AMERICAN JOURNAL OF PATHOLOGY (2017)
Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma
Hiroaki Itamochi et al.
BRITISH JOURNAL OF CANCER (2017)
Mismatch Repair Protein Expression in Clear Cell Carcinoma of the Ovary Incidence and Morphologic Associations in 109 Cases
Jennifer A. Bennett et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2016)
Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial
Toru Sugiyama et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives
Seiji Mabuchi et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2016)
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
Chris T. Williamson et al.
NATURE COMMUNICATIONS (2016)
Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma
Hisham Abou-Taleb et al.
ONCOTARGET (2016)
Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells
Suet-Yan Kwan et al.
ONCOTARGET (2016)
Polycomb and trithorax opposition in development and disease
Steven T. Poynter et al.
WILEY INTERDISCIPLINARY REVIEWS-DEVELOPMENTAL BIOLOGY (2016)
Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer
Ursula Matulonis et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
Junzo Hamanishi et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden
Michael S. Anglesio et al.
JOURNAL OF PATHOLOGY (2015)
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers
Benjamin G. Bitler et al.
NATURE MEDICINE (2015)
Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling
Ronald L. Chandler et al.
NATURE COMMUNICATIONS (2015)
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors
Jianfeng Shen et al.
CANCER DISCOVERY (2015)
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Ovary
Aikou Okamoto et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2014)
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Jonathan Ledermann et al.
LANCET ONCOLOGY (2014)
Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4
Pilar Ramos et al.
NATURE GENETICS (2014)
Germ line and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type
Leora Witkowski et al.
NATURE GENETICS (2014)
Cumulative Haploinsufficiency and Triplosensitivity Drive Aneuploidy Patterns and Shape the Cancer Genome
Teresa Davoli et al.
CELL (2013)
Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients
Kiyoshi Yoshino et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2013)
Increased Incidence of Severe Gastrointestinal Events With First-Line Paclitaxel, Carboplatin, and Vorinostat Chemotherapy for Advanced-Stage Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Alberto A. Mendivil et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2013)
Inactivating Mutations in SWI/SNF Chromatin Remodeling Genes in Human Cancer
Takahiro Oike et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2013)
Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy
Cigall Kadoch et al.
NATURE GENETICS (2013)
The Spectrum of SWI/SNF Mutations, Ubiquitous in Human Cancers
A. Hunter Shain et al.
PLOS ONE (2013)
Phase II Activity of Belinostat (PXD-101), Carboplatin, and Paclitaxel in Women With Previously Treated Ovarian Cancer
Don S. Dizon et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2012)
Clear cell carcinoma of the ovary: A report from the first Ovarian Clear Cell Symposium, June 24th, 2010
Michael S. Anglesio et al.
GYNECOLOGIC ONCOLOGY (2011)
Epigenetic Antagonism between Polycomb and SWI/SNF Complexes during Oncogenic Transformation
Boris G. Wilson et al.
CANCER CELL (2010)
Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas
Martin Koebel et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2010)
Clinicopathological Significance of Loss of ARID1A Immunoreactivity in Ovarian Clear Cell Carcinoma
Daichi Maeda et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2010)
Researchers find a new cancer gene and a possible link between ovarian cancer and endometriosis
[Anonymous]
WOMENS HEALTH (2010)
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
Sian Jones et al.
SCIENCE (2010)
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Kimberly C. Wiegand et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain
Jeremy M. R. Lambert et al.
CANCER CELL (2009)
Endometrioid and clear cell ovarian cancers - A comparative analysis of risk factors
Christina M. Nagle et al.
EUROPEAN JOURNAL OF CANCER (2008)
A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
Susan C. Modesitt et al.
GYNECOLOGIC ONCOLOGY (2008)
Serous ovarian, fallopian tube and primary peritoneal cancers: A comparative epidemiological analysis
Susan J. Jordan et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Risk factors for benign, borderline and invasive mucinous ovarian tumors: Epidemiological evidence of a neoplastic continuum?
Susan J. Jordan et al.
GYNECOLOGIC ONCOLOGY (2007)
A case of drug resistant clear cell ovarian cancer showing responsiveness to gemcitabine at first administration and at re-challenge
Gabriella Ferrandina et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary
David R. Crotzer et al.
GYNECOLOGIC ONCOLOGY (2007)
Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma
KQ Cai et al.
HUMAN PATHOLOGY (2004)
Largest subunits of the human SWI/SNF chromatin-remodeling complex promote transcriptional activation by steroid hormone receptors
H Inoue et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Share Paper
